Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 4/20 | 0.62 |
| ▸ | CYP11B2 | P19099 | 7/20 | 0.61 |
| ▸ | CYP11B1 | P15538 | 6/20 | 0.61 |
| ▸ | CYP17A1 | P05093 | 4/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 4/20 | 0.56 |
| ▸ | RAB9A | P51151 | 4/20 | 0.56 |
| ▸ | ITK | Q08881 | 2/20 | 0.54 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.54 |
| ▸ | CDK1 | P06493 | 2/20 | 0.54 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.54 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.54 |
| ▸ | PLK4 | O00444 | 1/20 | 0.54 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.54 |
| ▸ | AURKA | O14965 | 1/20 | 0.54 |
| ▸ | ABL1 | P00519 | 1/20 | 0.54 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1606084 | 0.89 | NPC1 (0.69) | CYP19A1CYP11B2CYP11B1CYP17A1KDM4E | |
| SCHEMBL4568278 | 0.85 | CYP19A1 (0.64) | CYP19A1CYP11B2CYP11B1CYP17A1KDM4E | |
| SCHEMBL3699661 | 0.82 | KDM4E (0.77) | KDM4EALDH1A1HPGDHSD17B10NPC1 | |
| SCHEMBL2789205 | 0.81 | CYP19A1 (0.68) | CYP19A1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL1536468 | 0.79 | KDM4E (0.58) | CYP19A1CYP11B2CYP11B1CYP17A1KDM4E | |
| SCHEMBL7945775 | 0.79 | KDM4E (0.73) | KDM4EALDH1A1HPGDNPC1RAB9A | |
| SCHEMBL4568280 | 0.78 | CYP19A1 (0.56) | CYP19A1CYP11B2CYP11B1CYP17A1KDM4E | |
| SCHEMBL1605273 | 0.78 | CYP19A1 (0.68) | CYP19A1KDM4EALDH1A1HPGDNPC1 | |
| SCHEMBL1605712 | 0.78 | CYP19A1 (0.68) | CYP19A1CYP11B2CYP11B1HPGDCDK5 | |
| SCHEMBL21812475 | 0.78 | CYP19A1 (0.56) | CYP19A1CYP11B2CYP11B1CYP17A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1935882-B1 | Bicyclic compounds | ASAHI KASEI PHARMA CORP (JP) | 2011-02-09 | — | — | EP | disclosed |
| US-7598284-B2 | Indazole compounds as B3 adrenoceptor agonist | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-10-06 | — | — | US | disclosed |
| US-7511069-B2 | Indazole compounds as β3 andrenoceptor agonist | ASAHI PHARMA CORPORATION (JP) | 2009-03-31 | — | — | US | disclosed |
| EP-1447400-B1 | BICYCLIC COMPOUND | ASAHI KASEI PHARMA CORP (JP) | 2008-09-17 | — | — | EP | disclosed |
| EP-1935882-A1 | Bicyclic compounds | Asahi Kasei Pharma Corporation (JP) | 2008-06-25 | — | — | EP | disclosed |
| US-20080076815-A1 | Indole compounds as B3 androceptor agonist | ASHI KASEI PHARMA CORPORATION (JP) | 2008-03-27 | — | — | US | disclosed |
| US-20080015242-A1 | INDOLE COMPOUNDS AS BETA3 ANDROCEPTOR AGONIST | ASAHI KASEI PHARMA CORPORATION (JP) | 2008-01-17 | — | — | US | disclosed |
| US-7271190-B2 | Indazole compounds as β3 adrenoceptor agonist | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-09-18 | — | — | US | disclosed |
| US-20050020602-A1 | Bicyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1447400-A1 | BICYCLIC COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2004-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020602-A1 | Bicyclic compound | GOT1, H1-0, HSD11B1 | CYP19A1 59/4885CYP11B2 22/4885CYP11B1 9/4885 |
| US-20080076815-A1 | Indole compounds as B3 androceptor agonist | OPRL1, NPBWR1, NPY4R | CYP19A1 1328/4885CYP11B2 251/4885CYP11B1 325/4885 |
| US-20080015242-A1 | INDOLE COMPOUNDS AS BETA3 ANDROCEPTOR AGONIST | ADRB3, ADRB2, OPRD1 | CYP19A1 1485/4885CYP11B2 282/4885CYP11B1 342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.